Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals (NASDAQ:PRTK) in a research report released on Wednesday, January 3rd. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Paratek Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, December 29th. Robert W. Baird reiterated a buy rating and set a $40.00 price objective on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. Guggenheim assumed coverage on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They issued a buy rating and a $44.00 target price for the company. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. Finally, BidaskClub cut shares of Paratek Pharmaceuticals from a sell rating to a strong sell rating in a report on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $39.63.

Shares of Paratek Pharmaceuticals (PRTK) opened at $15.45 on Wednesday. Paratek Pharmaceuticals has a 12 month low of $13.99 and a 12 month high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. The firm had revenue of $0.01 million during the quarter. sell-side analysts forecast that Paratek Pharmaceuticals will post -3.32 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Omni Partners LLP purchased a new stake in Paratek Pharmaceuticals in the 3rd quarter worth approximately $3,707,000. Alyeska Investment Group L.P. increased its stake in shares of Paratek Pharmaceuticals by 473.4% during the 3rd quarter. Alyeska Investment Group L.P. now owns 916,349 shares of the specialty pharmaceutical company’s stock worth $23,000,000 after purchasing an additional 756,535 shares during the last quarter. C WorldWide Group Holding A S increased its stake in shares of Paratek Pharmaceuticals by 46.8% during the 3rd quarter. C WorldWide Group Holding A S now owns 645,100 shares of the specialty pharmaceutical company’s stock worth $16,192,000 after purchasing an additional 205,700 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Paratek Pharmaceuticals by 481.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 63,787 shares of the specialty pharmaceutical company’s stock worth $1,538,000 after purchasing an additional 52,818 shares during the last quarter. Finally, Davidson Kempner Capital Management LP acquired a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth $6,727,000. Institutional investors own 75.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Paratek Pharmaceuticals (NASDAQ:PRTK) a $50.00 Price Target” was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.mareainformativa.com/2018/01/30/paratek-pharmaceuticals-prtk-pt-set-at-50-00-by-cantor-fitzgerald-updated-updated-updated.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.